Earlier data published by our group, from a smaller cohort of CBF‐AML had shown that HMA maintenance controlled MRD and extended remission in patients who had residual qRTPCR after FLAG‐based induction/consolidation or after ASCT.25 This evidence concerns the gene CEBPZ and acute myeloid leukemia.